Saturday, June 24, 2017 Print page
 
Centre of Inflammation and Metabolism (CIM)
 

Publications

To read the abstract, please click on the title of the publication of interest. If you want to access the publication on PubMed, please click on the PubMed ID.
To find specific publications, please use the sort and search functions. Please enter one word only as search term.

Click here to see all publications

31Plasma follistatin is elevated in patients with type 2 diabetes: relationship to hyperglycemia, hyperinsulinemia, and systemic low-grade inflammation.
Hansen J; Rinnov A; Krogh-Madsen R; Fischer CP; Andreasen AS; Berg RM; Moller K; Pedersen BK; Plomgaard P
Diabetes Metab Res Rev 2013; 29(6): 463-72
PubMed ID: 23564759

BACKGROUND: Plasma follistatin is elevated in patients with low-grade inflammation and insulin resistance as observed with polycystic ovary syndrome. In the present study, we evaluated plasma follistatin in patients with type 2 diabetes characterised by low-grade inflammation and assessed the acute effects of hyperglycemia, hyperinsulinemia and lipopolysaccharide (LPS) on plasma follistatin. Methods: Baseline plasma follistatin and inflammatory biomarkers were measured in a cross sectional study that involved 95 patients with type 2 diabetes and 103 matched controls. To determine the acute effect of hyperglycemia and hyperinsulinemia on follistatin, hyperglycemic and hyperinsulinemic-euglycemic clamps were performed in 5 healthy males. Furthermore, 15 patients with type 2 diabetes and 22 healthy controls were challenged with low-dose LPS to determine the effect on follistatin. RESULTS: Patients with type 2 diabetes have higher HOMA2-IR values mean [95% CI] 1.64 [1.40-1.93] versus mean 0.86 [0.75- 0.99], p < 0.001, and inflammatory markers compared with controls. Baseline plasma follistatin is elevated in patients with type 2 diabetes compared with controls mean 1564 [1456 - 1680] versus mean 1328 [1225-1440] ng/L, p = 0.003, and correlates with fasting glucose levels (r = 0.44, p < 0.0001), 2 h glucose (r = 0.48, p < 0.0001), HbA1c (r = 0.41, p < 0.0001), triacylglycerol (r = 0.28, p = 0.008) and total cholesterol (r = 0.33, p = 0.004) in patients but not in controls. No correlation exists between plasma follistatin and inflammatory biomarkers in either group. Neither hyperglycemia, hyperinsulinemia nor LPS increase plasma follistatin. CONCLUSIONS: Plasma follistatin is moderately elevated in patients with type 2 diabetes. Our findings suggest that this is not likely caused by hyperglycemia, hyperinsulinemia or systemic low-grade inflammation.



 
© 2017 Centre of Inflammation and Metabolism
www.inflammation-metabolism.dk